{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:13:31Z","timestamp":1791051211151,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,3,14]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Markedly additive antitumor activity with the combination of a selective survivin suppressant (YM155) and alemtuzumab in adult T-cell leukemia.<\/jats:p>","DOI":"10.1182\/blood-2012-05-427773","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T05:51:00Z","timestamp":1358315460000},"page":"2029-2037","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia"],"prefix":"10.1182","volume":"121","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[{"name":"Metabolism Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Pise-Masison","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Oncology, Center for Cancer Research, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna H.","family":"Shih","sequence":"additional","affiliation":[{"name":"Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[{"name":"Metabolism Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Janik","sequence":"additional","affiliation":[{"name":"Metabolism Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Conlon","sequence":"additional","affiliation":[{"name":"Metabolism Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Keating","sequence":"additional","affiliation":[{"name":"Astellas Pharma US Inc, Deerfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"Metabolism Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111810375898800_B1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.bloodjournal503481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases.","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"issue":"5838","key":"2019111810375898800_B2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/294268a0","article-title":"Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S\u00e9zary T-cell leukaemia.","volume":"294","author":"Poiesz","year":"1981","journal-title":"Nature"},{"issue":"6","key":"2019111810375898800_B3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.leu.2402458","article-title":"Role of tumor suppressor genes in the development of adult T cell leukemia\/lymphoma (ATLL).","volume":"16","author":"Hatta","year":"2002","journal-title":"Leukemia"},{"issue":"2","key":"2019111810375898800_B4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.V79.2.477.477","article-title":"Mutations of the p53 gene in adult T-cell leukemia.","volume":"79","author":"Sakashita","year":"1992","journal-title":"Blood"},{"issue":"5","key":"2019111810375898800_B5","first-page":"619","article-title":"[Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia\/lymphoma]. [in Japanese]","volume":"26","author":"Arima","year":"1999","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"2019111810375898800_B6","first-page":"164","article-title":"Phase I study of YK-176 (2\u2032-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma.","volume":"22","author":"Tobinai","year":"1992","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"2019111810375898800_B7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF02986621","article-title":"Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.","volume":"77","author":"Tobinai","year":"2003","journal-title":"Int J Hematol"},{"issue":"3","key":"2019111810375898800_B8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0609.2007.01016.x","article-title":"Treatment of adult T-cell leukemia\/lymphoma: past, present, and future.","volume":"80","author":"Ishitsuka","year":"2008","journal-title":"Eur J Haematol"},{"issue":"7","key":"2019111810375898800_B9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.1988.6.7.1088","article-title":"Major prognostic factors of adult patients with advanced T-cell lymphoma\/leukemia.","volume":"6","author":"Shimoyama","year":"1988","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111810375898800_B10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"issue":"34","key":"2019111810375898800_B11","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111810375898800_B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","article-title":"Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature.","volume":"23","author":"Tsukasaki","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111810375898800_B13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111810375898800_B14","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.","volume":"332","author":"Gill","year":"1995","journal-title":"N Engl J Med"},{"issue":"38","key":"2019111810375898800_B15","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.1073\/pnas.1010722107","article-title":"Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.","volume":"107","author":"Pancewicz","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"2019111810375898800_B16","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes.","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111810375898800_B17","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2006-07-036368","article-title":"IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia\/lymphoma.","volume":"109","author":"Ramos","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111810375898800_B18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111810375898800_B19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/15476910802129661","article-title":"Receptor-directed therapy of T-cell leukemias and lymphomas.","volume":"5","author":"Morris","year":"2008","journal-title":"J Immunotoxicol"},{"issue":"6","key":"2019111810375898800_B20","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia.","volume":"82","author":"Waldmann","year":"1993","journal-title":"Blood"},{"issue":"7","key":"2019111810375898800_B21","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/1078-0432.CCR-08-1254","article-title":"EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.","volume":"15","author":"O\u2019Mahony","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111810375898800_B22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111810375898800_B23","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood-2008-04-149658","article-title":"Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111810375898800_B24","first-page":"1083","article-title":"Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.","volume":"62","author":"Tan","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"2019111810375898800_B25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2004-05-1709","article-title":"Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"issue":"17","key":"2019111810375898800_B26","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2008-08-175901","article-title":"Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.","volume":"113","author":"Pise-Masison","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111810375898800_B27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrm830","article-title":"IAP proteins: blocking the road to death\u2019s door.","volume":"3","author":"Salvesen","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2019111810375898800_B28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14728222.12.4.463","article-title":"Targeting survivin in cancer therapy.","volume":"12","author":"Pennati","year":"2008","journal-title":"Expert Opin Ther Targets"},{"issue":"24","key":"2019111810375898800_B29","first-page":"6977","article-title":"IL-2Ralpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2Ralpha interaction.","volume":"60","author":"Phillips","year":"2000","journal-title":"Cancer Res"},{"issue":"3","key":"2019111810375898800_B30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies.","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"issue":"8","key":"2019111810375898800_B31","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/0008-5472.CAN-05-3248","article-title":"Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.","volume":"66","author":"Tirr\u00f2","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"2019111810375898800_B32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drup.2004.11.002","article-title":"Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.","volume":"7","author":"Van Geelen","year":"2004","journal-title":"Drug Resist Updat"},{"issue":"15","key":"2019111810375898800_B33","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1208490","article-title":"Survivin mediates resistance to antiandrogen therapy in prostate cancer.","volume":"24","author":"Zhang","year":"2005","journal-title":"Oncogene"},{"issue":"17","key":"2019111810375898800_B34","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"2019111810375898800_B35","first-page":"1043","article-title":"Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia.","volume":"60","author":"Nosaka","year":"2000","journal-title":"Cancer Res"},{"issue":"pt 23","key":"2019111810375898800_B36","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1242\/jcs.113.23.4363","article-title":"The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner.","volume":"113","author":"Zhao","year":"2000","journal-title":"J Cell Sci"},{"issue":"19","key":"2019111810375898800_B37","first-page":"6453","article-title":"Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"issue":"10","key":"2019111810375898800_B38","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1182\/blood-2005-01-0335","article-title":"Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine\/IFN-alpha-refractory adult T-cell leukemia.","volume":"106","author":"Mone","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111810375898800_B39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.leukres.2005.05.008","article-title":"Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.","volume":"30","author":"Ravandi","year":"2006","journal-title":"Leuk Res"},{"issue":"27","key":"2019111810375898800_B40","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111810375898800_B41","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1158\/0008-5472.CAN-04-3028","article-title":"Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer.","volume":"65","author":"R\u00f6del","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2019111810375898800_B42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ctrv.2009.05.003","article-title":"Survivin: a new target for anti-cancer therapy.","volume":"35","author":"Ryan","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2019111810375898800_B43","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1046\/j.1523-1747.1999.00776.x","article-title":"Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma.","volume":"113","author":"Grossman","year":"1999","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2019111810375898800_B44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.leu.2403281","article-title":"Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin\u2019s lymphoma.","volume":"18","author":"Ansell","year":"2004","journal-title":"Leukemia"},{"issue":"9","key":"2019111810375898800_B45","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-08-0161","article-title":"SPC3042: a proapoptotic survivin inhibitor.","volume":"7","author":"Hansen","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"36","key":"2019111810375898800_B46","doi-asserted-by":"crossref","first-page":"13239","DOI":"10.1073\/pnas.0405407101","article-title":"Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression.","volume":"101","author":"Chang","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"2019111810375898800_B47","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1200\/JCO.2008.17.2064","article-title":"Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.","volume":"26","author":"Tolcher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111810375898800_B48","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/cncr.26510","article-title":"A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.","volume":"118","author":"Cheson","year":"2012","journal-title":"Cancer"},{"issue":"10","key":"2019111810375898800_B49","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s00262-005-0102-x","article-title":"Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.","volume":"55","author":"Wobser","year":"2006","journal-title":"Cancer Immunol Immunother"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/11\/2029\/1363567\/2029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/11\/2029\/1363567\/2029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T01:46:28Z","timestamp":1644111988000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/11\/2029\/31054\/Markedly-additive-antitumor-activity-with-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-427773","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}